Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03FFA
|
|||
| Former ID |
DIB006047
|
|||
| Drug Name |
HB-AS02V
|
|||
| Synonyms |
HBV vaccine (adjuvanted), Henogen; Hepatitis B virus vaccine (adjuvanted), Henogen
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 3 | [1] | |
| Company |
Henogen SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cell mediated immunity response (CMIR) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00291980) A Study to Compare the Immune Response and Safety Elicited by Henogen's Adjuvanted Hepatitis B Vaccine Compared to Aventis Pasteur MSD's Hepatitis B Vaccine in Pre-Dialysis and Dialysis Patients Who Responded to Previous Hepatitis B Vaccination But Lost Antibody.. U.S. National Institutes of Health. | |||
| REF 2 | Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.